Icotinib after surgery for early lung cancer with EGFR mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a pill called icotinib, given after lung cancer surgery, to see if it helps prevent the cancer from returning in people with early-stage, EGFR-mutant non-small cell lung cancer. It is a real-world study, meaning it looks at how the treatment works in routine practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must have been completely removed by surgery.
- Your cancer stage must be early (stage IA2 with high-risk features or stage IB).
- Your tumor must test positive for an EGFR mutation (a specific gene change).
- Your cancer type must be non-squamous, such as adenocarcinoma or a mix that is mostly adenocarcinoma.
- You should not have received any anti-cancer treatment for your lung cancer before surgery (except surgery itself) or before the cancer came back.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This Phase 2 trial studies whether an EGFR-targeted pill, given after surgery, can reduce the chance of lung cancer coming back. It specifically looks at people whose tumors have certain EGFR changes and where “minimal residual disease” (tiny leftover cancer) is being used to guide treatment.
This trial tests whether giving the targeted drug icotinib along with chemotherapy before surgery can help people with a specific type of lung cancer (EGFR-mutated adenocarcinoma) that can be removed. The treatment aims to shrink the tumor and improve outcomes.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.